{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-125062","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.117527+00:00","generated_at":"2026-05-15T08:51:57.821581+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026","bullets":["Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.","Cash, equivalents and investments $453.1M as of Dec 31, 2025, expected to fund operations through 2027.","Phase 2 ZEPHYR trial for schizophrenia: target enrollment (n=300) expected April 2026; topline results Q3 2026.","Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results expected Q3 2026.","FDA Fast Track granted for ML-007C-MA in Alzheimer's disease psychosis; VISTA trial topline H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-125062","json":"https://secwatch.observer/filing/0001193125-26-125062.json","markdown":"https://secwatch.observer/filing/0001193125-26-125062.md","text":"https://secwatch.observer/filing/0001193125-26-125062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/mplt-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:51:57.821581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e73c7775234c8104e0e82673eab82bbc577a63e","claim":"MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.","evidence_excerpt":"Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2025"},{"label":"Net income","value":"$79.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f0b0aeccfaf4011469d1be9688dff1987378b85c","claim":"MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.","evidence_excerpt":"For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2025"},{"label":"Net income","value":"$161.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}